Advertisement

Tumor Biology

, Volume 37, Issue 11, pp 14873–14883 | Cite as

FABP5 correlates with poor prognosis and promotes tumor cell growth and metastasis in cervical cancer

  • Wei Wang
  • Hong-juan Chu
  • Yan-chun Liang
  • Jia-ming Huang
  • Chun-liang Shang
  • Hao Tan
  • Duo Liu
  • Yun-he Zhao
  • Tian-yu Liu
  • Shu-zhong Yao
Original Article

Abstract

Fatty acid-binding protein 5 (FABP5) was found in our previous study to be a potential biomarker for lymph node metastasis of cervical cancer. However, the roles of FABP5 in cervical cancer remain unclear. In the present study, FABP5 expression was found to be significantly upregulated in cervical cancer tissues, and high FABP5 expression was significantly correlated with lymph node metastasis, lymphovascular space invasion, the International Federation of Gynecology and Obstetrics (FIGO) stage, and tumor size. Moreover, FABP5 was an independent factor for poor prognosis in cervical cancer patients. Silencing of FABP5 inhibited cell proliferation, colony formation, cell migration, and invasion in vitro. Furthermore, FABP5 silencing significantly reduced tumor growth and lung metastases in a murine allograft model in vivo. In addition, FABP5 silencing decreased the expression of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) in vitro and in vivo. Collectively, these findings indicated that FABP5 plays an important role in the carcinogenesis and metastasis of cervical cancer, and FABP5 may be a novel predictor for prognostic assessment of cervical cancer patients.

Keywords

Cervical cancer Metastasis Prognosis FABP5 

Notes

Acknowledgments

This work is supported by the Sun Yat-sen University Clinical Research 5010 Program (grant number 2007010), the Guangdong Natural Science Fund (grant number 2016A030310147, S2013010015448), and the Science and Technology Program of Guangzhou (grant number 201510010289).

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA. A Cancer Journal for Clinicians. 2015;65:87–108.CrossRefGoogle Scholar
  2. 2.
    Lin LF, Chuang CH, Li CF, Liao CC, Cheng CP, Cheng TL, et al. Zbrk1 acts as a metastatic suppressor by directly regulating mmp9 in cervical cancer. Cancer Res. 2010;70:192–201.CrossRefPubMedGoogle Scholar
  3. 3.
    Chen YF, Chiu WT, Chen YT, Lin PY, Huang HJ, Chou CY, et al. Calcium store sensor stromal-interaction molecule 1-dependent signaling plays an important role in cervical cancer growth, migration, and angiogenesis. Proc Natl Acad Sci U S A. 2011;108:15225–30.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    He SY, Shen HW, Xu L, Zhao XH, Yuan L, Niu G, et al. Foxm1 promotes tumor cell invasion and correlates with poor prognosis in early-stage cervical cancer. Gynecol Oncol. 2012;127:601–10.CrossRefPubMedGoogle Scholar
  5. 5.
    Wang W, Jia HL, Huang JM, Liang YC, Tan H, Geng HZ, et al. Identification of biomarkers for lymph node metastasis in early-stage cervical cancer by tissue-based proteomics. Br J Cancer. 2014;110:1748–58.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Storch J, Corsico B. The emerging functions and mechanisms of mammalian fatty acid-binding proteins. Annu Rev Nutr. 2008;28:73–95.CrossRefPubMedGoogle Scholar
  7. 7.
    Jeong CY, Hah YS, Cho BI, Lee SM, Joo YT, Jung EJ, et al. Fatty acid-binding protein 5 promotes cell proliferation and invasion in human intrahepatic cholangiocarcinoma. Oncol Rep. 2012;28:1283–92.PubMedGoogle Scholar
  8. 8.
    Adamson J, Morgan EA, Beesley C, Mei Y, Foster CS, Fujii H, et al. High-level expression of cutaneous fatty acid-binding protein in prostatic carcinomas and its effect on tumorigenicity. Oncogene. 2003;22:2739–49.CrossRefPubMedGoogle Scholar
  9. 9.
    Campos B, Centner FS, Bermejo JL, Ali R, Dorsch K, Wan F, et al. Aberrant expression of retinoic acid signaling molecules influences patient survival in astrocytic gliomas. Am J Pathol. 2011;178:1953–64.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Liu RZ, Graham K, Glubrecht DD, Germain DR, Mackey JR, Godbout R. Association of fabp5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy. Am J Pathol. 2011;178:997–1008.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Chen Y, Lin C, Liu Y, Jiang Y. Hmgb1 promotes hcc progression partly by downregulating p21 via erk/c-myc pathway and upregulating mmp-2. Tumour Biol. 2015.Google Scholar
  12. 12.
    Fang LY, Wong TY, Chiang WF, Chen YL. Fatty-acid-binding protein 5 promotes cell proliferation and invasion in oral squamous cell carcinoma. J Oral Pathol Med. 2010;39:342–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Levi L, Lobo G, Doud MK, von Lintig J, Seachrist D, Tochtrop GP, et al. Genetic ablation of the fatty acid-binding protein fabp5 suppresses her2-induced mammary tumorigenesis. Cancer Res. 2013;73:4770–80.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Jing C, Beesley C, Foster CS, Rudland PS, Fujii H, Ono T, et al. Identification of the messenger rna for human cutaneous fatty acid-binding protein as a metastasis inducer. Cancer Res. 2000;60:2390–8.PubMedGoogle Scholar
  15. 15.
    Jing C, Beesley C, Foster CS, Chen H, Rudland PS, West DC, et al. Human cutaneous fatty acid-binding protein induces metastasis by up-regulating the expression of vascular endothelial growth factor gene in rat rama 37 model cells. Cancer Res. 2001;61:4357–64.PubMedGoogle Scholar
  16. 16.
    Powell CA, Nasser MW, Zhao H, Wochna JC, Zhang X, Shapiro C, et al. Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability. Oncotarget. 2015;6:6373–85.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Libra M, Scalisi A, Vella N, Clementi S, Sorio R, Stivala F, et al. Uterine cervical carcinoma: role of matrix metalloproteinases. Int J Oncol. 2009;34:897–903 .ReviewPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Wei Wang
    • 1
  • Hong-juan Chu
    • 2
  • Yan-chun Liang
    • 1
  • Jia-ming Huang
    • 1
  • Chun-liang Shang
    • 1
  • Hao Tan
    • 1
  • Duo Liu
    • 1
  • Yun-he Zhao
    • 1
  • Tian-yu Liu
    • 1
  • Shu-zhong Yao
    • 1
  1. 1.Department of Obstetrics and Gynecology, the First Affiliated HospitalSun Yat-sen UniversityGuangzhouChina
  2. 2.Department of Otorhinolaryngology Head and Neck Surgerythe Third Affiliated Hospital of Southern Medical UniversityGuangzhouChina

Personalised recommendations